Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
May 04 2022 - 08:30AM
Business Wire
Omeros Corporation (NASDAQ: OMER), today announced that the
company will issue its first quarter financial results for the
period ended March 31, 2022, on Tuesday, May 10, 2022, after the
market closes. Omeros management will host a conference call and
webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
to discuss the financial results as well as recent developments and
highlights.
Conference Call Details
To access the live conference call via phone, please dial (844)
831-4029 from the United States and Canada or (920) 663-6278
internationally. The participant passcode is 1198541. Please dial
in approximately 10 minutes prior to the start of the call. A
telephone replay will be available for one week following the call
and may be accessed by dialing (855) 859-2056 from the United
States and Canada or (404) 537-3406 internationally. The replay
passcode is 1198541.
To access the live and subsequently archived webcast of the
conference call, go to Omeros’ website at
https://investor.omeros.com/upcoming-events.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic diseases, including complement-mediated
diseases and cancers related to dysfunction of the immune system,
as well as addictive and compulsive disorders. Omeros’ lead MASP-2
inhibitor narsoplimab targets the lectin pathway of complement and
is the subject of a biologics license application pending before
FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy. Narsoplimab is
also in multiple late-stage clinical development programs focused
on other complement-mediated disorders, including IgA nephropathy,
atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros’
inhibitor of MASP-3, the key activator of the alternative pathway
of complement, is initiating a Phase 1b clinical program in
paroxysmal nocturnal hemoglobinuria (PNH). In addition to its
complement franchise, Omeros has ongoing cutting-edge programs in
addiction treatments, immuno-oncology therapeutics and human CAR-T
and adoptive T cell therapy systems. More information about Omeros
and its programs is available at www.omeros.com and in Omeros’
annual, quarterly and current reports filed with the U.S.
Securities and Exchange Commission (SEC), which can be accessed at
www.omeros.com under “Investors & News — Financial Information
— SEC Filings” and on the SEC’s website at www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504005477/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Feb 2024 to Mar 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2023 to Mar 2024